What is the primary driver of Stryker's significant net earnings increase in the first nine months of 2005?

The substantial increase in net earnings for the first nine months of 2005 was largely due to a significant comparison benefit. In the third quarter of 2004, Stryker recorded a large charge of $120.8 million for purchased in-process research and development related to the SpineCore acquisition. This charge significantly reduced net earnings in the prior-year period, making the current year's reported net earnings appear much higher. Excluding these charges, adjusted net earnings showed a more moderate, but still strong, growth of 23%.

How did the acquisition of eTrauma.com Corp. and SpineCore, Inc. impact the financial results?

The acquisition of eTrauma.com Corp. in Q1 2005 for approximately $50 million expanded Stryker's MedSurg Equipment segment with image management software and did not materially impact reported operating results or pro forma results. The SpineCore acquisition in Q3 2004, however, resulted in a $120.8 million charge for purchased in-process R&D in that period. While SpineCore's results are included from its acquisition date, they were not material to overall operating results. The eTrauma acquisition was accounted for using the purchase method, with a portion of the price allocated to goodwill and identifiable intangibles.

What is the significance of the planned repatriation of foreign earnings?

Stryker's Board approved a plan to repatriate approximately $722 million of undistributed foreign earnings under the American Jobs Creation Act of 2004. This plan allows for repatriation at a reduced tax cost. Stryker recorded a $31.3 million tax charge in the third quarter of 2005 related to this repatriation, which will occur in the fourth quarter of 2005 and be reinvested domestically. This repatriation is expected to provide additional cash resources for future investments and growth initiatives.

What is the outlook for Stryker's financial performance in the near future?

Stryker's outlook is optimistic. The company expects full-year 2005 diluted net earnings per share to approximate $1.75, with anticipated net sales growth of 14% to 15%. For 2006, the company projects diluted net earnings per share of approximately $2.10, excluding the impact of adopting new stock option accounting standards. This forecast is supported by continued strong growth in orthopaedic procedures and the company's broad product portfolio, though potential pricing pressures in certain markets are noted.

SYK 10-Q Quarterly Report Q3 FY2005 — Revenue, Net Income, EPS

Summary

Stryker Corporation reported strong financial performance for the nine months ended September 30, 2005, with net sales increasing by 16% to $3.6 billion and net earnings soaring by 62% to $489.5 million compared to the prior year period. This growth was driven by robust sales across both its Orthopaedic Implants and MedSurg Equipment segments, with notable increases in trauma, spine, and knee implant systems, as well as powered surgical instruments and endoscopic products. The company also saw significant operating income growth, up 52% year-over-year for the nine-month period. Key financial events during the period included the acquisition of eTrauma.com Corp. for approximately $50 million, which expanded its MedSurg segment offerings. The company also announced plans to repatriate approximately $722 million of foreign earnings under the American Jobs Creation Act, incurring a $31.3 million tax charge in Q3 2005. Looking ahead, Stryker provided an optimistic outlook, projecting full-year 2005 diluted EPS of approximately $1.75 and anticipating continued strong sales growth in 2006, with diluted EPS projected at $2.10 (excluding stock option expense impact). While the company experienced a significant year-over-year increase in net earnings, this was heavily influenced by a large charge for purchased in-process R&D in Q3 2004. Excluding this and the Q3 2005 repatriation tax charge, adjusted net earnings showed a more consistent growth of 23% for the first nine months of 2005. The company's liquidity remains strong, with significant operating cash flow generation and ample borrowing capacity to fund future growth initiatives and acquisitions.

Key Highlights

1Stryker reported a 16% increase in net sales to $3.6 billion for the first nine months of 2005, driven by strong performance in both Orthopaedic Implants and MedSurg Equipment segments.
2Net earnings for the nine months ended September 30, 2005, surged by 62% to $489.5 million, or $1.21 per diluted share, compared to $303.0 million, or $0.76 per diluted share, in the prior year.
3Operating income saw a substantial increase of 52% to $740.2 million for the first nine months of 2005.
4The company acquired eTrauma.com Corp. for approximately $50 million in Q1 2005 to expand its product offerings in the MedSurg Equipment segment.
5Stryker announced plans to repatriate $722 million of foreign earnings, incurring a $31.3 million tax charge in Q3 2005.
6The company provided an optimistic outlook, forecasting full-year 2005 diluted EPS of approximately $1.75 and $2.10 for 2006.
7Operating cash flow increased significantly to $482.2 million for the first nine months of 2005, up from $288.7 million in the prior year.

STRYKER CORP Quarterly Report for Q3 Ended Sep 30, 2005

Summary

Key Highlights

Frequently Asked Questions